RxDoctor Payments Data

Balasubramanian Shanmugam, MD

Internal Medicine · Bristol, CTNPI 1285807768

Payments from drug & device makers

$3,597in general payments, 2019–2025

Across 210 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$716
  • Gilead$565
  • Merck$410
  • Johnson & Johnson$187
  • GSK$176
  • Lilly USA, LLC$168
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,31192%
  • Education$2868%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,597 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$134,520
Medicare patients
267
Services billed
1,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin151$143,108
EliquisApixaban130$109,347
OzempicSemaglutide89$94,777
RybelsusSemaglutide65$63,221
StribildElviteg/Cob/Emtri/Tenofo Disop12$58,082
FarxigaDapagliflozin Propanediol56$51,752
XareltoRivaroxaban56$43,584
MounjaroTirzepatide35$38,081
DescovyEmtricitabine/Tenofov Alafenam12$30,110
Synjardy XrEmpagliflozin/Metformin Hcl30$18,030
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$17,486
JanumetSitagliptin Phos/Metformin Hcl12$16,673
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$11,655
Breo ElliptaFluticasone/Vilanterol23$11,597
Nitrofurantoin12$8,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Jentadueto Xr$148$167,272193 claims
Novo NordiskOzempic, Rybelsus$137$157,998154 claims
PfizerEliquis$153$109,347130 claims
GileadStribild, Descovy$565$88,19224 claims
AstraZenecaFarxiga$716$51,75256 claims
Johnson & JohnsonXarelto$187$43,58456 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$176$40,73863 claims
Lilly USA, LLCMounjaro$168$38,08135 claims
MerckJanumet$410$16,67312 claims
AbbVieSynthroid$50$2,25525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Bristol

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →